CBD for Social Anxiety Disorder: What the Clinical Research Actually Shows

Social anxiety disorder affects 15 million Americans — and fewer than 37% ever seek treatment. A completed Phase 2 trial at NYU Langone Health, plus a wave of clinical and neuroimaging research, is building a compelling scientific case that CBD may offer a genuinely new path forward. Here is a deep, research-backed look at what the evidence actually shows.

Social Anxiety Disorder: A Condition That Is Vastly Undertreated

Social anxiety disorder (SAD) is far more than shyness. It is a diagnosable psychiatric condition characterized by intense, persistent fear of social or performance situations — a dread of being observed, judged, humiliated, or embarrassed that is so severe it impairs daily functioning. According to the National Institute of Mental Health (NIMH), SAD affects an estimated 7.1% of U.S. adults in any given year — approximately 15 million people — and 12.1% of Americans will experience it at some point in their lives. It typically begins around age 13 and can persist for decades without treatment.

The disorder carries serious consequences. Among adults with SAD, 29.9% experience serious impairment in their ability to work, maintain relationships, and carry out daily activities. Yet according to the Anxiety and Depression Association of America (ADAA), a striking 36% of people with social anxiety disorder report experiencing symptoms for 10 or more years before seeking help — and only about 36.9% of those with anxiety disorders ever receive treatment at all.

Current first-line treatments include selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and benzodiazepines. While effective for some, these options have significant limitations: SSRIs can take 4–6 weeks to work, carry side effects, and fail to achieve complete remission in 40–60% of patients. Benzodiazepines carry dependence risk. CBT, while highly effective, is expensive, requires trained therapists, and has limited availability. This treatment gap is one of the most pressing reasons researchers are urgently exploring new pharmacological options — including CBD.

The NYU Langone Health Phase 2 Trial: A Landmark Study

The most rigorously designed CBD study for social anxiety disorder to date is the Phase 2 randomized controlled trial conducted by NYU Langone Health, led by principal investigator Dr. Naomi M. Simon and colleagues including Matteo Malgaroli, Kristin L. Szuhany, and Esther Blessing. Registered as NCT05571592 on ClinicalTrials.gov, this double-blind, placebo-controlled trial enrolled 60 participants (20 per group) aged 18–45 who met diagnostic criteria for SAD.

Study design and protocol

Participants were randomized to one of three groups for three weeks: CBD 800mg daily (400mg twice daily), CBD 400mg daily (200mg twice daily), or placebo. The CBD used was a pharmaceutical-grade, hemp-derived oral capsule formulation with enhanced bioavailability using nanodomain technology, with CBD purity of 98% or greater — specifically designed to be suitable for Phase 3 trials.

The trial incorporated two sophisticated biological measurement approaches that set it apart from earlier studies. At week 2, participants underwent a standardized stress task measuring real-time anxiety responses using the Visual Analogue Mood Scale (VAMS). At week 3, they completed a two-day fear learning and extinction protocol with functional MRI (fMRI) neuroimaging — measuring amygdala activation in response to fearful versus neutral faces, and ventromedial prefrontal cortex (vmPFC) activation during fear extinction recall. The Liebowitz Social Anxiety Scale (LSAS) — the gold-standard clinician-rated measure for SAD severity — was used to assess symptom change.

The trial completed in November 2025. It was designed as an R61 milestone study — a specific NIH funding mechanism used to establish a biological 'signature' of a treatment's mechanism before proceeding to a larger definitive clinical trial (the R33 phase). The goal was not simply to measure symptom improvement, but to identify the specific brain pathways through which CBD acts — providing the mechanistic roadmap for future Phase 3 trials.

Full citation: Simon NM, Malgaroli M, Santacatterina M, Szuhany KL, Feldman B, Blessing E. "Randomized Placebo-controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder (R61)." ClinicalTrials.gov Identifier: NCT05571592. Sponsor: NYU Langone Health. Completed: November 2025.

What Brain Imaging Reveals About CBD and Social Anxiety

To understand why the NYU trial's neuroimaging focus matters so much, it helps to understand the neuroscience of social anxiety disorder. SAD is not simply a thought pattern — it has identifiable, measurable signatures in the brain. Two regions are especially central: the amygdala and the ventromedial prefrontal cortex (vmPFC).

The amygdala is the brain's threat-detection center. In people with SAD, the amygdala shows hyperactivation in response to social stimuli — particularly fearful or evaluative facial expressions. This overactivation drives the intense fear response that characterizes the disorder. The vmPFC, by contrast, plays a key role in fear extinction — the brain's process of learning that a previously feared stimulus is now safe. In anxiety disorders, vmPFC function is often impaired, making it harder to 'unlearn' fear responses through therapy or exposure.

Earlier fMRI research has already shown that CBD administration attenuates amygdala activation in response to fearful faces and reduces connectivity between the amygdala and the anterior cingulate cortex — effects that correlated with reduced subjective anxiety in participants. A study published in Psychopharmacology (Springer/Nature, 2022) by Camsari et al. and colleagues specifically examined CBD's neurocognitive effects on emotional processing, finding that CBD shifted attention away from threatening emotional stimuli toward more neutral ones, and reduced amygdala reactivity — a key neurobiological target for SAD treatment.

Citation: "The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study." Psychopharmacology, Springer Nature (2022). DOI: 10.1007/s00213-022-06070-3.

The Science of Fear Extinction: Why CBD May Enhance Therapy

One of the most exciting dimensions of CBD research in social anxiety is its potential to enhance fear extinction — the same neurological process that underlies exposure-based therapy, the most effective psychological treatment for anxiety disorders. Research has demonstrated that CBD facilitates extinction learning of fear memories in humans, and that cannabinoid signaling in the amygdala, hippocampus, and vmPFC plays a key role in encoding and retaining extinction memories.

This has profound clinical implications. If CBD can enhance vmPFC activation during fear extinction recall — which the NYU trial specifically measured — it could potentially be used as an adjunct to exposure-based cognitive behavioral therapy, making each therapy session more neurologically effective. In other words, CBD might not just reduce symptoms on its own but could amplify the benefits of existing treatments. A separate Phase 2 trial at UC San Diego (NCT05823753), also now completed, specifically investigated CBD's effects on anxiety reactivity and anandamide levels, examining whether CBD's anxiolytic effects operate through endocannabinoid system engagement.

Citation: "Endocannabinoid System Engagement to Reduce Anxiety Reactivity with Cannabidiol in Social Anxiety Disorder." ClinicalTrials.gov Identifier: NCT05823753. Sponsor: University of California, San Diego. Phase 2. Completed.

The Evidence Before NYU: Key Human Studies

The 2011 landmark public speaking study (Bergamaschi et al.)

The foundational human trial for CBD and social anxiety was published in Neuropsychopharmacology in 2011 by Bergamaschi, Queiroz, Chagas, and colleagues at the University of São Paulo. In a double-blind, randomized design, 24 treatment-naive patients with generalized SAD received either 600mg CBD or placebo before a simulated public speaking test (SPST) — one of the most ecologically valid anxiety-induction methods used in research, and the social situation most feared by people with SAD. CBD-treated patients showed significantly attenuated anxiety during the speech. They also showed measurably different regional cerebral blood flow (rCBF) patterns — decreased rCBF in the left parahippocampal gyrus and hippocampus (regions showing pathological overactivation in SAD) and increased rCBF in the right posterior cingulate cortex. Critically, no sedation was observed — the anxiety reduction was specific, not a general numbing effect.

Full citation: Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. "Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients." Neuropsychopharmacology (2011). Vol. 36, pp. 1219–1226. DOI: 10.1038/npp.2011.6. PMC: PMC3079847.

The inverted U-shaped dose curve: finding the sweet spot

A critical finding across CBD and anxiety research is the inverted U-shaped dose-response curve. A study published in Frontiers in Pharmacology (Linares et al., 2019, PMC5425583) used a real-life public speaking paradigm and found that CBD 300mg significantly reduced anxiety during and after a speech, while CBD 100mg and CBD 900mg did not show significant effects versus placebo. This dose-response pattern — where both too little and too much CBD are less effective than the optimal middle dose — has been replicated across multiple studies and is consistent with CBD's mechanism of action through 5-HT1A serotonin receptors. At very high doses, CBD also activates TRPV1 receptors, which can actually counteract the anxiolytic effects by facilitating glutamate release.

Citation: Linares IMP, Guimaraes FS, Eckeli A, et al. "No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study." AND: "Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life." Frontiers in Pharmacology (2019). PMC ID: PMC5425583.

CBD for teenage social anxiety: a 4-week trial (Masataka, 2019)

A double-blind trial published in Frontiers in Psychology (2019) by Masataka examined the effects of 300mg CBD daily for four weeks in 37 Japanese teenagers (ages 18–19) with SAD and avoidant personality disorder. At the end of four weeks, CBD significantly reduced anxiety measured by the Fear of Negative Evaluation Questionnaire and the Liebowitz Social Anxiety Scale — the same scale used in the NYU trial — compared to placebo. This study demonstrated that chronic (not just acute) CBD administration is effective, and specifically targeted the population where SAD most commonly begins.

Full citation: Masataka N. "Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders." Frontiers in Psychology (2019). DOI: 10.3389/fpsyg.2019.02466.

McLean Hospital / Harvard: full-spectrum CBD Phase 2 data (2022)

A Phase 2 open-label clinical trial conducted at McLean Hospital / Harvard Medical School by Dahlgren, Lambros, Smith, Sagar, and Gruber (MIND Program) and published in Communications Medicine (Nature, 2022) assessed four weeks of full-spectrum high-CBD sublingual solution (9.97mg/mL CBD) in 14 outpatients with moderate-to-severe anxiety. The trial found significant improvements on the Beck Anxiety Inventory and the Overall Anxiety Severity and Impairment Scale (p<0.001 for both), along with secondary improvements in mood, sleep quality, quality of life, and executive function — notably without any impairment of cognitive performance. This is one of the first studies to show CBD improving cognition alongside anxiety.

Full citation: Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. "Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial." Communications Medicine, Nature (2022). DOI: 10.1038/s43856-022-00202-8. PMC ID: PMC9628346.

How CBD Works on Social Anxiety: The Mechanisms

One of CBD's most important characteristics is that it works through multiple simultaneous biological pathways — not through a single receptor like most psychiatric medications. A 2024 systematic review of randomized controlled CBD trials for anxiety disorders published in PMC (Martinotti et al., PMC11595441) and a comprehensive PMC review (PMC7480724) have identified at least four key mechanisms:

5-HT1A serotonin receptor agonism: CBD acts as a partial agonist at the 5-HT1A serotonin receptor — the same receptor subtype targeted by buspirone, a common anti-anxiety medication, and related to the receptors modulated by SSRIs like Prozac and Zoloft. This is the most well-supported anxiolytic mechanism for CBD, confirmed by animal studies where blocking 5-HT1A eliminated CBD's anti-anxiety effects.

Anandamide enhancement: CBD inhibits FAAH (fatty acid amide hydrolase), the enzyme that breaks down anandamide — the body's own 'bliss molecule' endocannabinoid. By slowing anandamide's breakdown, CBD raises its levels, reducing anxiety reactivity. The UC San Diego trial (NCT05823753) specifically measured anandamide blood levels as a biomarker.

Amygdala and limbic system modulation: CBD reduces hyperactivation in the amygdala and parahippocampal regions that drive fear responses in SAD — directly measurable on fMRI. This is the primary target of the NYU Langone neuroimaging protocol.

vmPFC enhancement for fear extinction: By supporting vmPFC activation during fear extinction recall, CBD may help the brain consolidate extinction learning — essentially helping people 'unlearn' social fear more effectively. This positions CBD as a potential adjunct to exposure therapy.

Citation: "Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence." PMC ID: PMC7480724. AND: "The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials." PMC ID: PMC11595441 (2024).

The 2024 Meta-Analysis: Quantifying CBD's Effect on Anxiety

A 2024 meta-analysis pooling data from 8 clinical trials with 316 total participants found that CBD produced a substantial and statistically significant effect on anxiety, with a Hedges' g of -0.92 — a large effect size by psychiatric research standards. For context, many FDA-approved anxiety medications achieve effect sizes in the range of 0.3–0.5. Multiple individual trials report 40–50% reductions in anxiety scores with CBD treatment. A 2024 Journal of Cannabis Research review identified 22 planned or ongoing CBD and anxiety trials — underscoring the scale of current scientific interest.

Additional Active Trials

Beyond NYU Langone and UC San Diego, several other active or recently completed trials are advancing CBD's evidence base for SAD and related anxiety conditions:

EmpowerPharm Phase 2 Multicenter Trial (NCT05600114): A completed randomized, double-blind, quadruple-masked, placebo-controlled Phase 2 trial comparing CBD 150mg twice daily versus CBD 300mg twice daily versus placebo for SAD across multiple centers.

MIT / Massachusetts General Hospital Trial (NCT05649059): A completed randomized placebo-controlled study using FDA-approved Epidiolex before the Trier Social Stress Test (TSST) — the gold standard for ethically inducing stress — followed by fMRI neuroimaging measuring emotional and self-referential processing in 50 SAD participants.

CBD Effects on Fear Extinction in Social Phobia (NCT06123702): A trial examining CBD's ability to potentiate fear extinction in SAD, using galvanic skin response and self-reported fear during an electrical-stimulation fear conditioning and extinction paradigm — directly testing the therapy-enhancement hypothesis.

What This Means: Honest Context

The evidence for CBD in social anxiety disorder is more advanced than for almost any other CBD therapeutic application, with multiple completed Phase 2 trials, a growing meta-analysis base, and mechanistic neuroimaging data now available. However, important limitations remain. As a 2024 Cannigma review noted, most completed studies have been small, with the two most statistically powered studies still not using double-blind RCT designs. Long-term efficacy data beyond 4–6 weeks does not yet exist. Standardized dosing protocols are still being established. And there is a significant gap between the pharmaceutical-grade CBD used in clinical trials and over-the-counter consumer products, which a 2024 Frontiers in Pharmacology analysis found to be mislabeled in one-third of cases.

CBD is not FDA-approved for social anxiety disorder. Anyone experiencing significant social anxiety should consult a psychiatrist or licensed mental health professional. That said, the body of evidence building around CBD and SAD is now substantial enough that it demands serious scientific and clinical attention — and the NYU Langone R61 trial, with its fMRI biomarker data and two-dose design, is the most important study to date in moving this research toward the definitive Phase 3 trial it deserves.

The Bottom Line

Social anxiety disorder is the third most common psychiatric condition in the world, yet most people who have it suffer in silence for years before seeking help — if they seek help at all. The convergence of mechanistic brain imaging research, multiple completed Phase 2 trials, a 2024 meta-analysis showing large effect sizes, and a clear biological model of how CBD acts on the anxious brain represents a genuine turning point. At Tonify, we believe in following the science honestly. The evidence for CBD and social anxiety is among the strongest in the entire CBD research landscape — and it is growing rapidly.

Full Sources & Citations

1. Simon NM et al. "Randomized Placebo-controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder (R61)." Phase 2, NYU Langone Health. ClinicalTrials.gov: NCT05571592. Completed November 2025. https://clinicaltrials.gov/study/NCT05571592

2. Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. "Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients." Neuropsychopharmacology (2011). Vol. 36, pp. 1219–1226. DOI: 10.1038/npp.2011.6. PMC: PMC3079847. https://pmc.ncbi.nlm.nih.gov/articles/PMC3079847/

3. Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. "Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial." Communications Medicine, Nature (2022). DOI: 10.1038/s43856-022-00202-8. PMC: PMC9628346. https://pmc.ncbi.nlm.nih.gov/articles/PMC9628346/

4. Masataka N. "Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders." Frontiers in Psychology (2019). DOI: 10.3389/fpsyg.2019.02466. https://www.frontiersin.org/articles/10.3389/fpsyg.2019.02466/full

5. Linares IMP et al. "Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life." Frontiers in Pharmacology (2019). PMC ID: PMC5425583. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425583/

6. "The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study." Psychopharmacology, Springer Nature (2022). DOI: 10.1007/s00213-022-06070-3. https://link.springer.com/article/10.1007/s00213-022-06070-3

7. "Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety." ScienceDirect / PMC (2022). PMC ID: PMC9983614. https://pmc.ncbi.nlm.nih.gov/articles/PMC9983614/

8. "The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials." PMC (2024). PMC ID: PMC11595441. https://pmc.ncbi.nlm.nih.gov/articles/PMC11595441/

9. "Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence." PMC (2020). PMC ID: PMC7480724. https://pmc.ncbi.nlm.nih.gov/articles/PMC7480724/

10. "Endocannabinoid System Engagement to Reduce Anxiety Reactivity with Cannabidiol in Social Anxiety Disorder." Phase 2 trial. ClinicalTrials.gov: NCT05823753. Sponsor: University of California, San Diego. https://clinicaltrials.gov/study/NCT05823753

11. "Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder." Phase 2, EmpowerPharm Inc. ClinicalTrials.gov: NCT05600114. https://clinicaltrials.gov/study/NCT05600114

12. "Investigating the Effects of Cannabidiol on Social Anxiety Disorder." MIT / Massachusetts General Hospital. ClinicalTrials.gov: NCT05649059. https://clinicaltrials.gov/study/NCT05649059

13. "Cannabidiol Effects on Fear Extinction in Social Phobia." ClinicalTrials.gov: NCT06123702. https://clinicaltrials.gov/study/NCT06123702

14. Social Anxiety Disorder Statistics. National Institute of Mental Health (NIMH). https://www.nimh.nih.gov/health/statistics/social-anxiety-disorder

15. Facts & Statistics — Anxiety & Depression Association of America (ADAA). https://adaa.org/understanding-anxiety/facts-statistics

16. CBD for Anxiety and Stress: What the Science Shows. The Cannigma (March 2026). https://cannigma.com/research/cbd-for-anxiety-stress-evidence-dosage-safety/

17. "Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research." PMC ID: PMC7917759. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917759/

Disclaimer: This article is for informational and educational purposes only. The statements in this blog have not been evaluated by the Food and Drug Administration. Tonify products are not intended to diagnose, treat, cure, or prevent any disease. CBD is not FDA-approved for social anxiety disorder. Always consult a qualified psychiatrist, psychologist, or healthcare professional if you are experiencing symptoms of social anxiety disorder or any other mental health condition.